Gilead Sciences (GILD, market cap 104B) is the manufacturer and owner of patents for remdesivir. Remdesivir is a competitor to hydroxychloroquine as COVID-19 treatment, although more expensive, less tested, and, apparently, less efficient. HCQ is a generic drug with very low profit margins.
9 out of 50 members of the Panel on COVID-19 Treatment Guidelines disclosed that they had financial ties to Gilead from May 1, 2019, to March 31, 2020. Yes, the reporting period covered only 10 months, and ended three weeks before publication of the report.
Also, look at how flattering the fake news media and Google are to Gilead and remdesivir:
and compare this with the coverage of HCQ:
Each search has been done in a browser in the clean state in Texas on April 23 round 11am.
via Science Defies Politics
April 23, 2020 at 11:30AM
Iowa Climate Science Education 